Russell Skibsted - Jul 24, 2025 Form 4/A - Amendment Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Financial Officer
Signature
/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Jul 24, 2025
Transactions value $
$0
Form type
4/A - Amendment
Date filed
9/18/2025, 04:23 PM
Date Of Original Report
Jul 28, 2025
Previous filing
Jul 18, 2024
Next filing
Oct 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SKIBSTED RUSSELL Chief Financial Officer C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH /s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact 2025-09-18 0001308105

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PCSA Restricted Stock Units 28K Jul 24, 2025 Common Stock 28K $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting of 50% on 7/16/25 and the remainder upon achievement of certain criteria.

Remarks:

Amendment filed to retract the prior Form 4, which was filed in error.